Key Highlights

  • RKDA shares are trading down 17.83% today at $0.1401, against a 52-week range of $0.1110 to $5.2290.
  • Stockholders approved a reverse split of between 1-for-2 and 1-for-10 on September 10.
  • Second-quarter Revenue was $1.44 million, down 1%, with a net loss to common stockholders of $6.3 million.
  • Cash was $4.2 million at June 30, after a $4 million private Placement closed in June.
  • Stockholders' Equity of $633,000 sits below Nasdaq's $2.5 million minimum.

No New Announcement Found as Arcadia Shares Slide to $0.1401

Arcadia Biosciences (NASDAQ:RKDA) shares are trading down 17.83% today at $0.1401. No company-specific announcement was identified for the move, and the stock closed the October 19 session at $0.1450 after a 12.01% decline, so the latest drop extends a weak run.

Arcadia is a Dallas-based producer and marketer of wellness products with roots in agricultural innovation dating to 2002. Its main Brand is Zola coconut water. Market data lists a market Capitalization of about $349,000 as of October 20 and a 52-week range of $0.1110 to $5.2290. Roughly 1.26 million shares, about 52.3% of those outstanding on the record date, were present at the September annual meeting, which implies a share count of around 2.4 million.

Two Nasdaq Notices: $1.00 Bid Price and the $2.5 Million Equity Floor

Nasdaq notified Arcadia on August 4 that its closing bid price had been under $1.00 for 30 consecutive Business days. The company has until February 1, 2027 to regain compliance, which requires at least 10 straight closes at or above $1.00, and may seek a second 180-day period.

A second letter on August 31 said stockholders' equity of $633,000 at June 30 fell short of the $2.5 million minimum. A compliance plan was due October 15, and Nasdaq may grant up to 180 days if it accepts the plan. At the September 10 annual meeting, stockholders approved a reverse split between 1-for-2 and 1-for-10, which the board can carry out before June 30, 2027.

Zola Sales Rebound Contrasts With a $6.3 Million Second-Quarter Net Loss

Second-quarter revenue was $1,443,000, a 1% decline, and first-half revenue was $2,543,000, down 4%. Management blamed low inventory and longer shipping times, and said July Zola sales above $740,000 exceeded half of the entire second-quarter total.

The net loss to common stockholders was $6.3 million, or $2.09 per share, driven by a $2.8 million unrealized loss on a held investment, a $5.4 million valuation loss on the June private placement and $651,000 of offering costs. Loss from continuing operations was only $496,000, and selling, general and administrative costs fell $1.0 million.

Cash used in operations was $319,000, leaving $4.2 million on hand. The company said it will need more funding, which could dilute holders.

Espresso Launch, Dilution Risk and Listing Deadlines Set the Agenda

A new 1-liter Zola espresso is planned for the fourth quarter, with three more products due in the first half of 2027. The February 1, 2027 bid price deadline, the equity compliance plan outcome and any reverse split decision are the next dated items for a stock priced near $0.14. The sources reviewed did not confirm whether the equity compliance plan was filed or accepted. Management has also said it may evaluate strategic alternatives, and the company still reports a stake in another listed company's shares that it values each quarter, a source of Earnings swings.